DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®.
Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions.
| DATE/TIMES: | MONDAY, JUNE 12, 2023 |
| 10:00 a.m. – 11:00 a.m. | |
| LOCATION: | MannKind |
| 40 Taylor Street (Danbury, CT) | |
| VISUALS/SOUND: | - Governor Lamont tours facility with MannKind CEO Dr. Michael Castagna and COO Lauren Sabella |
| - Construction underway on “clean rooms” and spray dry equipment in new manufacturing space | |
| - Demonstration of MannKind’s innovative Technosphere® particle and device technologies | |
| - Production personnel producing the particle technology used as part of our inhaled insulin (Afrezza®) as well as Tyvaso DPI | |
| MANNKIND: | MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. |
| CONTACT: | MannKind Corporate Communications |
| Christie Iacangelo (on-site) | |
| (818) 292-3500 (mobile) | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$5.94 |
| Daily Change: | 0.01 0.17 |
| Daily Volume: | 4,758,737 |
| Market Cap: | US$1.640B |
December 16, 2024 November 07, 2024 November 05, 2024 November 04, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
